M
Marker Therapeutics D
D
MRKR
1.38500
USD
0.02
(1.09%)
Market Closed
Volume
0
EPS
-1
Div Yield
-
P/E
-3
Market Cap
23,092,281
Title: Marker Therapeutics
Sector: Healthcare
Industry: Biotechnology
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphomaand pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).